Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7147 | Cl-HIBO |
| Subtype-selective and strongly desensitising AMPA receptor agonist; selective for GluR1 and GluR2 subunit-containing receptors (EC50 values are 4.7, 1.7, 2700 and 1300 μM for rat recombinant homomeric GluR1, 2, 3 and 4 receptors respectively). | |
| BCC7150 | GW 7647 |
| Potent and highly selective PPARα agonist (EC50 values are 6, 1100 and 6200 nM for human PPARα, PPARγ and PPARδ receptors respectively). Modulates oleate metabolism and mitochondrial enzyme gene expression in mature myotubules in vitro. Has lipid-lowering effects following oral administration in vivo. Reduces NO production in macrophages; exhibits anti-inflammatory properties. | |
| BCC7152 | K 252a |
| Non-selective protein kinase inhibitor; analog of staurosporine. Inhibits PKC (IC50 = 32.9 nM), Ca2+/calmodulin-stimulated phosphodiesterases (IC50 = 1.3 - 2.9 μM), MLCK (Ki = 20 nM) and receptor tyrosine kinases. Inhibits the oncogenic properties of MET; prevents autophosphorylation and activation of downstream effectors (MAPK, Akt). | |
| BCC7153 | Autocamtide-2-related inhibitory peptide |
| Selective and potent calmodulin-dependent protein kinase II (CaM kinase II) inhibitor (IC50 = 40 nM). Selective over PKC, PKA and CaM kinase IV (IC50 > 10 μM). | |
| BCC7162 | CL 218872 |
| Benzodiazepine agonist displaying selectivity for α1 subunit-containing GABAA receptors (Ki values are 130, 1820, 1530, > 10000, 490 and > 10000 nM for α1, α2, α3, α4, α5 and α6-subunit containing receptors respectively). Orally active anxiolytic and anticonvulsant in vivo. | |
| BCC7164 | R-96544 hydrochloride |
| Potent, selective 5-HT2 receptor antagonist; displays some selectivity for 5-HT2A receptors (Ki = 1.6 nM). IC50 values are 2.2, 310, 2400, 3700, > 5000 and > 5000 nM for 5-HT2, α1-adrenergic, D2 dopamine, 5-HT1, 5-HT3 and β-adrenergic receptors respectively. Inhibits 5-HT-induced platelet aggregation and pressor responses in vivo. | |
| BCC7166 | HexylHIBO |
| Group I mGlu receptor antagonist (Ki values are 140 and 110 μM at mGlu1a and mGlu5a receptors respectively). Decreases sEPSCs in rat pyramidal neurons in vitro. | |
| BCC7167 | (S)-HexylHIBO |
| Group I mGlu receptor antagonist (Kb values are 30 and 61 μM at mGlu1a and mGlu5a receptors respectively). Enantiomer of hexylHIBO. | |
